Other Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.OtherRespiratoryRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. OtherRespiratoryRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Oxford BioTherapeutics signs collaboration with Bristol Myers SquibbNext: Pulmonary fibrosis drug developer Avalyn files IPO Related Stories Other ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer pharminent June 2, 2026 Other ASCO26: Symptom-tracking app helps advanced cancer patients pharminent June 2, 2026 Other All eyes on Revolution, bispecific antibodies and more at ASCO26 pharminent May 26, 2026
